Edition:
United States

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

16.28EUR
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
€16.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
60,404
52-wk High
€16.40
52-wk Low
€8.41

Chart for

About

Mithra Pharmaceuticals SA is a Belgium-based company that provides pharmaceutical services. It was founded in 1999.

Overall

Beta: --
Market Cap(Mil.): €550.62
Shares Outstanding(Mil.): 34.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.45 17.28
EPS (TTM): -- -- --
ROI: -- 14.04 35.61
ROE: -- 15.50 17.17

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* ‍MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®​

Feb 08 2018

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* ‍MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY​

Jan 25 2018

BRIEF-Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic

* MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC

Dec 27 2017

BRIEF-Mithra Pharmaceuticals Announces Injectables Agreement With GSP

* MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES

Dec 14 2017

BRIEF-Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs

* FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS

Dec 11 2017

BRIEF-Mithra Announces Valorization Of French Subsidiary

* SUCCESSFULLY DIVESTED ITS FRENCH AFFILIATE, MITHRA FRANCE‍​

Dec 07 2017

BRIEF-Mithra Pharmaceuticals Announces Update On Clinical Study Progress For Estelle And Donesta‍​

* ANNOUNCES AN UPDATE ON THE CLINICAL STUDY PROGRESS FOR ESTELLE AND DONESTA‍​

Nov 30 2017

BRIEF-Mithra Pharmaceuticals announces 36-month shelf life extension for Tibelia​

* ‍MITHRA ANNOUNCES 36-MONTH SHELF LIFE EXTENSION FOR TIBELIA​

Nov 22 2017

BRIEF-Mithra Pharmaceuticals: ‍positive outcome of Myring commercial batch bioequivalence study​

* ‍POSITIVE OUTCOME OF MYRING COMMERCIAL BATCH BIOEQUIVALENCE STUDY

Nov 17 2017

BRIEF-Mithra Pharmaceuticals ‍completes recruitment for Estelle Phase III study in US and Canada​

* ‍COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US AND CANADA​

Oct 30 2017

Earnings vs. Estimates